Amoxicillin Clavulanate in Treatment of Acute Otitis Media

University of Turku320 enrolled

Overview

This is a prospective, randomized, double-blind, placebo controlled one-center study carried out in primary care setting of the health center of City of Turku, Finland. The study patients will be allocated to one of the two parallel treatment groups (amoxicillin-clavulanate or placebo). The hypothesis is that the symptoms and signs of acute otitis media are resolved more effectively with antimicrobial treatment than with placebo. Furthermore, this study aims at finding out prognostic factors that could help to direct antimicrobial treatment for correct subgroups of young patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

320

Conditions

Acute Otitis Media

Interventions

amoxicillin-clavulanateDRUG

Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.

PlaceboDRUG

Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 35 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Acute otitis media * Age 6 - 35 mo Exclusion Criteria: * Spontaneous perforation of the tympanic membrane and drainage * Systemic or nasal corticosteroid therapy within 3 preceding days * Antihistamine therapy with 3 preceding days * Oseltamivir therapy within 3 preceding days * Allergy to amoxicillin/penicillin * Tympanostomy tube present in tympanic membrane * Clinical evidence of infection requiring systemic antimicrobial treatment * Documented Ebstein Barr virus infection within 7 preceding days * Down syndrome or other condition to affect middle ear infections * Known immunodeficiency * Vomiting or another symptom to violate per oral dosage * Poor parental co-operation due to language or other reasons * Use of any investigational drugs during the 4 preceding weeks

Locations (2)

Department of Pediatrics, Turku University Hospital

Turku, Finland

Unnamed facility

Turku, Finland

Outcomes

Primary Outcomes

Compare time to treatment failure in children receiving amoxicillin-clavulanate to children receiving placebo

Time frame: During the first 8 days of follow-up

Secondary Outcomes

Time to resolution of symptoms in children receiving amoxicillin-clavulanate to children receiving placebo

Time frame: Duration of study

Time to resolution of acute inflammatory signs of middle ear

Time frame: Duration of study

Compare the 2 treatment groups regarding the doses of analgesic medication and number of days analgesics are administered by children's parents

Time frame: First 7 days of follow-up

Compare the 2 treatment groups regarding the number of days with absenteeism from day care and/or parental absenteeism from work

Time frame: First 7 days of follow-up

Compare the incidence of adverse events accompanying the 2 treatment regimens

Time frame: Duration of study

Time to resolution of middle ear fluid in the ear(s) that is affected on study day 1

Time frame: Duration of study

Time to relapse of acute otitis media

Time frame: Study days 9-17

Time to first reinfection of acute otitis media

Time frame: From study day 18 to the end of follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.